View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 29, 2022

Vela Diagnostics launches new panels to detect cancer biomarkers

The new panels can detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded tissue specimens.

Vela Diagnostics has launched new focused (60 genes) and comprehensive (525 genes) next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens.

The new pan-cancer gene panels include the focused OncoKey SL 60 Plus Panel and comprehensive OncoKey SL 525 Plus Panel.

They can detect insertions/deletions (INDELs), copy number variations (CNVs), single nucleotide variations (SNVs), fusions, splice variants, microsatellite instability (MSI), oncogenic viruses and bacteria in a single assay.

Featuring a sample-to-result workflow, the new NGS-based panels can evaluate up to 64 samples in a single sequencing run.

They require 2.5 hours of hands-on time and generate results within five days.

Vela Diagnostics CEO and executive chairman Sam Dajani said: “Vela Diagnostics is planning to launch our OncoKey 60 and 525 Plus Panels in Q4 2022 in the USA and Asia Pacific.

“Using these panels on Vela Diagnostics ’ automated workflow will reduce human error and minimise sample cross-contamination, which can be generated by using a manual workflow.

“In addition, our VELA Analytics solutions and services can identify and interpret genetic variants in tumours, making it possible to provide actionable options for healthcare and research professionals quickly and accurately.”

The company noted that the OncoKey SL 60 and 525 Plus Panels provide high sample traceability, from automated sample extraction to data quality control (QC).

They can be adapted to current lab situations and their workflow is wrapped around Illumina sequencing platforms.

Last November, the US Food and Drug Administration (FDA ) granted emergency use authorisation (EUA) to Vela DiagnosticsViroKey SARS-CoV-2 reverse transcription-polymerase chain reaction Test v2.0 with expanded automation options.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network